Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics is expected to show strong revenue growth over the next few years, aided by their innovative product, the iLet Bionic Pancreas. The company has consistently beat estimates since going public in 2024, and we forecast continued growth in both revenue and gross margin. Despite recent challenges regarding FDA compliance, we believe their pipeline and potential market share gains make Beta Bionics a strong investment opportunity at current levels.

Bears say

Beta Bionics is facing operational risk due to a recent FDA warning letter, as well as a decline in NPS sales and a slower than expected commercialization timeline for their patch product. The company's positive gross margin lift and cash on hand may not be enough to offset these concerns and the company's dependence on the PBP channel may also limit growth potential. As a result, the negative outlook on Beta Bionics stock is justified.

BBNX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 10 analysts, BBNX has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.